One of the most prevalent neurodegenerative diseases is Alzheimer's disease (AD). The hallmarks of AD include the accumulation of amyloid plaques and neurofibrillary tangles, which cause related secondary diseases, progressive neurodegeneration, and ultimately death. The most prevalent cell type in the human central nervous system, astrocytes, are crucial for controlling neuronal function. Glial fibrillary acidic protein (GFAP) is released from tissue into the bloodstream due to astrocyte breakdown in neurological diseases. Increased levels of GFAP in the serum can function as blood markers and be an effective prognostic indicator to help diagnose neurological conditions early on, from stroke to neurodegenerative diseases. The human central nervous system (CNS) is greatly affected by diseases associated with blood GFAP levels. These include multiple sclerosis, intracerebral hemorrhage, glioblastoma multiforme, traumatic brain injuries, and neuromyelitis optica. GFAP demonstrates a strong diagnostic capacity for projecting outcomes following an injury. Furthermore, the increased ability to identify GFAP protein fragments helps facilitate treatment, as it allows continuous screening of CNS injuries and early identification of potential recurrences. GFAP has recently gained attention due to data showing that the plasma biomarker is effective in identifying AD pathology. AD accounts for 60-70% of the approximately 50 million people with dementia worldwide. It is critical to develop molecular markers for AD, whose number is expected to increase to about 3 times and affect humans by 2050, and to investigate possible targets to confirm their effectiveness in the early diagnosis of AD. In addition, most diagnostic methods currently used are image-based and do not detect early disease, i.e. before symptoms appear; thus, treatment options and outcomes are limited. Therefore, recently developed methods such as point-of-care (POC), on-site applications, and enzyme-linked immunosorbent assay-polymerase chain reaction (ELISA-PCR) that provide both faster and more accurate results are gaining importance. This systematic review summarizes published studies with different approaches such as immunosensor, lateral flow, POC, ELISA-PCR, and molecularly imprinted polymer using GFAP, a potential blood biomarker to detect neurological disorders. Here, we also provide an overview of current approaches, analysis methods, and different future detection strategies for GFAP, the most popular biosensing field.

Neuropeptide Y (NPY) is one of the most abundant neuropeptides in the human brain, and its levels in the blood change in neurodegenerative and neuroimmune disorders. This indicates that NPY may serve as a diagnostic and monitoring marker for associated disorders. In this paper, an electrochemical immunosensor was created to detect NPY biomarkers using a novel immobilization technique. The proposed biosensor system enables accurate, specific, cost-effective, and practical biomarker analysis. Indium tin oxide-coated polyethylene terephthalate (ITO-PET) sheets were treated with hexamethylene diisocyanate (HMDC) to covalently immobilize antibodies. Electrochemical impedance spectroscopy (EIS) and cyclic voltammetry (CV) techniques were used to analyze each step of the biosensors. The proposed NPY biosensor has a broad linear detection range (0.01–100 pg mL⁻¹), a low limit of detection (LOD) (0.02968 pg mL⁻¹), and a low limit of quantification (LOQ) (0.0989 pg mL⁻¹). Atomic force microscopy (AFM) was used to support in the optimization process, study the surface morphology, and visualize it. Studies of repeatability, reproducibility, storage, and Kramers–Kronig transformation were conducted during electrochemical characterization. After analytical experiments, the biosensor’s responses to human serum samples were evaluated. According to the obtained data, the error margin is small, and the created biosensor offers a great deal of promise for the clinical measurement of NPY.